{"entity":{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Cetuximab, Afatinib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","summary":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 is a phase 1/2 interventional study registered as NCT03785249 by Mirati Therapeutics Inc., with 731 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2026-06-23. Interventions recorded: MRTX849, Pembrolizumab, Cetuximab, Afatinib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03785249","url":"https://clinicaltrials.gov/study/NCT03785249"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","cetuximab","afatinib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03785249","phase":"1/2","setting":"A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1","sponsor":"Mirati Therapeutics Inc.","enrolled":731,"outcomes":[]},"route":"/trials/nct03785249/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}